2024
Modeling lung adenocarcinoma metastases using patient-derived organoids
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, Chow-Tsang L, Tian H, Mastrogiacomo B, He D, Connolly J, Lengel H, Caso R, Dunne E, Fick C, Rocco G, Sihag S, Isbell J, Bott M, Li B, Lito P, Brennan C, Bilsky M, Rekhtman N, Adusumilli P, Mayo M, Imielinski M, Jones D. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Reports Medicine 2024, 5: 101777. PMID: 39413736, PMCID: PMC11513837, DOI: 10.1016/j.xcrm.2024.101777.Peer-Reviewed Original ResearchConceptsMetastasis modelLung adenocarcinomaAutologous peripheral blood mononuclear cellsEarly-stage lung cancerMechanisms of drug resistancePeripheral blood mononuclear cellsBlood mononuclear cellsEfficacy of treatmentLung cancer metastasisLung adenocarcinoma metastasisDistant metastasisStudy clonalityAdenocarcinoma metastasisLung cancerMononuclear cellsDrug resistanceMetastasisSuppress metastasisIndividual patientsTumor evolutionCancer metastasisHuman metastasesPatientsBiological featuresRNA sequencing
2023
Mediastinal Staging in Non–Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy
Dunne E, Fick C, Jones D. Mediastinal Staging in Non–Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy. Journal Of Clinical Oncology 2023, 41: 3785-3790. PMID: 37267507, PMCID: PMC10419653, DOI: 10.1200/jco.23.00867.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungEndosonographyHumansLung NeoplasmsLymph NodesMediastinoscopyMediastinumNeoplasm StagingConceptsMediastinal lymph nodesCell lung cancerConfirmatory mediastinoscopyFine-needle aspirationPositron emission tomographyLymph nodesNodal metastasisEBUS-FNALung cancerEndobronchial ultrasound-guided fine-needle aspirationOncology Grand Rounds seriesNegative findingsUltrasound-guided fine-needle aspirationThoracic Surgeons guidelinesRandomized noninferiority trialStandard of careTumor genomic analysisOwn clinical practiceResectable NSCLCN1 diseaseNodal diseaseMediastinal stagingAccurate stagingForceps biopsySurgeons guidelinesGenomic mapping of metastatic organotropism in lung adenocarcinoma
Lengel H, Mastrogiacomo B, Connolly J, Tan K, Liu Y, Fick C, Dunne E, He D, Lankadasari M, Satravada B, Sun Y, Kundra R, Fong C, Smith S, Riely G, Rudin C, Gomez D, Solit D, Berger M, Li B, Mayo M, Matei I, Lyden D, Adusumilli P, Schultz N, Sanchez-Vega F, Jones D. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell 2023, 41: 970-985.e3. PMID: 37084736, PMCID: PMC10391526, DOI: 10.1016/j.ccell.2023.03.018.Peer-Reviewed Original ResearchConceptsActionable alterationsPrimary tumorMetastasis-free survivalHigh mutational burdenAPOBEC mutational signatureSolid histological subtypeMetastatic burdenClinicopathological featuresHistological subtypesLung adenocarcinomaMutational burdenLiver lesionsInactivation of TP53Tumor genomicsMetastasisMetastatic organotropismUnknown significanceGenomic alterationsOrganotropismMutational signaturesTumorsNumber alterationsAlterationsBurdenChromosomal instability